Drugs / AST-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06687941 | Mar 2025 → Dec 2027 expected | hepatocellular carcinoma, non-small cell lung carcinoma | Aptamer Sciences, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05794659 | Nov 2023 → Nov 2025 overdue | ovarian cancer | Aston Sci. Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794659 ↗ |
| Modality | Vaccine | “adjuvant therapeutic cancer vaccine AST-201” NCT05794659 ↗ |
| Route | Other | “will be given intradermally” NCT05794659 ↗ |
| Target | GPC3 | “targeting GPC3-positive advanced solid tumors” NCT06687941 ↗ |